The beginning of the end for Type 1 diabetes: A new view from immunotherapy science was posted on OpenAccessGovernment.org, 16 December 2020. Jean Van Rampelbergh PhD, VP Clinical & Regulatory at Imcyse SA, introduces ImotopesTM a cutting-edge immunotherapy science with an excellent safety profile that could cure Type 1 diabetes or drastically change treatment options
It is commonly perceived that diabetes is a disease that has been solved through the use of insulin and diet change, sadly this is not the case. Although in the past 40 years innovations have improved the lives of diabetes patients, there have been no new advances that can take the place of daily insuli
n injections. In the exciting world of new medical approaches, Imcyse SA, from the Walloon Region of Belgium, has developed a disruptive approach based on immunotherapeutic principles and logic. In December, the first patient with recent-onset Type 1 diabetes (T1D) was treated in the Company’s Phase 2 clinical trial – IMPACT – with IMCY-0098, an ImotopeTM that specifically targets the autoimmune response destroying insulin-producing cells without harming the rest of the immune system.
ImotopesTM: A short-term disease modifying treatment with potential long-term effect in Type 1 diabetes; good safety through a targeted approach
In T1D, the pancreas is damaged due to an aberrant immune response. This damage causes the organ to stop producing insulin, the hormone that controls blood-sugar levels. In the majority of cases, T1D begins in children and adolescents, but also affect adults. The Imcyse approach is a unique and highly specific technology that specifically targets immune cells involved in the destruction of the diseased organ and aims to interfere early enough in the disease progression, so the aberrant immune response is halted and the immune system is recalibrated.
Imcyse’s new drug candidate IMCY-0098 is intended to stop the destruction of beta-cells and block the autoimmune response. Through this simple intervention, the pancreas maintains its natural ability to produce insulin. ImotopeTM science is designed as a short-term treatment regimen with the potential to provide long-term sustained effects by modifying the disease instead of only controlling the symptoms. This targeted approach has demonstrated a good safety profile observed in a Phase 1 study.
Read more: The beginning of the end for Type 1 diabetes
New CGM device developed in Wales removes need to use needles for people was posted on Diabetes Research & Wellness Foundation (DRWF.org.us), 22 January 2021. The world’s first non-invasive, real-time continuous glucose monitor could make huge impact on global diabetes community.
Afon Technology, a Wales-based device manufacturer, is developing a portable, non-invasive, real-time continuous glucose monitor. The device, which closely resembles a wrist-watch, is tipped by developers as having the potential to completely radicalize the lives of people living with diabetes who need to monitor blood glucose levels as part of their management of the condition. It will measure blood glucose levels without the need to penetrate the skin at all, making it easier to manage the condition and therefore reducing the risk of diabetes-related complications.
New insulin molecule can self-regulate blood sugar was reported on ScienceDaily.com, 3 December 2020. Researchers have developed a new insulin molecule that will make blood sugar regulation both easier and safer for those with type 1 diabetes.
Researchers from the University of Copenhagen and biotech firm Gubra have developed a new insulin molecule that, in the future, will ensure that diabetics receive just the right amount of insulin.
The insulin on the market today is unable to identify whether a patient with type 1 diabetes needs a small or large effect from the insulin, which lowers blood sugar.
“That is why we have developed the first step towards a kind of insulin that can self-adjust according to a patient’s blood sugar level. This has tremendous potential to vastly improve the lives of people with type 1 diabetes,” explains Professor Knud J. Jensen, of the University of Copenhagen’s Department of Chemistry, one of the researchers behind a new study on this new insulin.